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Abstract
Purpose—The PI3K/Akt signaling axis contributes to the dysregulation of many dominant 
features in breast cancer including cell proliferation, survival, metabolism, motility and genomic 
instability. While multiple studies have demonstrated that basal-like or triple negative breast 
tumors have uniformly high PI3K/Akt activity, genomic alterations that mediate dysregulation of 
this pathway in this subset of highly aggressive breast tumors remain to be determined.
Methods—In this study, we present an integrated genomic analysis based on the use of a PI3K 
gene expression signature as a framework to analyze orthogonal genomic data from human breast 
tumors, including RNA expression, DNA copy number alterations, and protein expression. In 
combination with data from a genome-wide RNA-mediated interference screen in human breast 
cancer cell lines we identified essential genetic drivers of PI3K/Akt signaling.
Results—Our in silico analyses identified SOX4 amplification as a novel modulator of PI3K/Akt 
signaling in breast cancers and in vitro studies confirmed its role in regulating Akt 
phosphorylation.
Conclusions—Taken together, these data establish a role for SOX4 mediated PI3K/Akt 
signaling in breast cancer and suggest that SOX4 may represent a novel therapeutic target and/or 
biomarker for current PI3K-family therapies.
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INTRODUCTION
Breast cancer heterogeneity can be observed clinically by widely varying therapeutic 
responses and at a molecular level by the myriad of genetic alterations driving tumorigenesis 
[1–6]. Clinically, triple negative breast cancer (TNBC), which is largely synonymous with 
the basal-like molecular subtype of breast cancer, accounts for 15–20% of breast tumors 
representing ~20,000 new cases and ~10,000 deaths each year in the United States [3, 7]. 
Given the lack of drug-able targets expressed by TNBC tumors, including the lack of 
estrogen receptor (ER) and the HER2 oncogene, few therapeutic options exist beyond 
currently utilized cytotoxic therapies, and the overall prognosis for these patients remains 
poor.
Many previous studies, including The Cancer Genome Atlas (TCGA) project, have reported 
increased phosphatidylinositol-3-OH kinase (PI3K) signaling in basal-like tumors. This 
pathway mediates, among other processes, cell cycle progression and survival, [3, 8–10] and 
is highly activated in this subset of tumors despite a low incidence (~7%) of PIK3CA 
activation mutations. While studies from the TCGA and others have noted copy number 
alterations or mutations in PTEN (35%), INPP4B (30%) and activation of multiple receptor 
tyrosine kinases, including EGFR (7%), ERBB2 (4%) and IGFR1 (2%), in addition to other 
mutations that may affect aberrant PI3K signaling in basal-like tumors, it remains to be 
determined whether additional mechanisms may contribute to pathway activity and/or the 
observed lack of response to PI3K family inhibitors [3, 8, 11–14].
To identify genomic alterations mediating PI3K/Akt signaling, specifically those that may 
represent novel therapeutic targets and/or biomarkers to current therapies, we utilized an 
integrative genomic strategy based on experimentally-derived gene expression signatures 
[6]. By analyzing orthogonal proteomic and genomic data from the TCGA in conjunction 
with data from a genome-wide RNAi proliferation screen in breast cancer cell lines we 
identified SOX4 as a putative novel regulator of PI3K/Akt signaling and in vitro studies 
confirmed the role of this gene in mediating Akt phosphorylation.
MATERIALS AND METHODS
Gene expression data
RNA sequencing data (n=1,031) from human tumors (Supplemental Table 1) were acquired 
from the TCGA data portal (https://tcga-data.nci.nih.gov/tcga/) and processed as previously 
described [15]. PAM50 classification as well as calculation of the PI3K [6, 16], PIK3CA 
[17], PTEN Deleted and PTEN Wildtype [18] signatures was performed as previously 
described [1, 6, 19]. Illumina HT-29 v3 expression data for the METABRIC (Molecular 
Taxonomy of Breast Cancer International Consortium) project (n=1,992) was acquired from 
the European Genome-phenome Archive at the European Bioinformatics Institute (https://
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www.ebi.ac.uk/ega/) and data were median centered [4]. Expression data for a panel of 51 
breast cancer cell lines was acquired from GEO (GSE12777) [20]. Affymetrix U133+2 data 
were MAS5.0 normalized using Affymetrix Expression Console (ver1.2.1.20), and log2 
transformed. Expression probes were collapsed using the median gene value with the 
GenePattern [21] module CollapseProbes.
Reverse Phase Protein Array (RPPA) data
RPPA data were acquired (October 24, 2013) from The Cancer Proteome Atlas data portal 
(http://app1.bioinformatics.mdanderson.org/tcpa/_design/basic/index.html). Replication 
Based Normalized RPPA data (n=733) containing expression levels for 187 proteins and 
phosphorylated proteins (Supplementary Table 1) were used to identify differentially 
expressed proteins. Samples were separated into high (top quartile) and low (all other) 
subgroups based on pathway score and a t-test used to assess differences in expression for 
each protein. Additionally, a Spearman-rank correlation was used to compare the overall 
correlation between pathway activity and protein expression.
Affymetrix SNP 6.0 copy number data
Affymetrix SNP 6.0-derived copy number data (Firehose run April 16, 2014) were acquired 
from the Firehose data portal (http://gdac.broadinstitute.org/) for the 1,031 samples 
(Supplementary Table 1) for which both CN and gene expression data were available. 
Pathway-specific CN alterations were identified as previously described [6]. Briefly, a 
Spearman rank correlation (both positive and negative), was used to compare gene-level 
segment scores with pathway activity score. Secondly, the frequency of copy number gains 
(including high level amplification and gains) or losses (loss of heterozygosity or deletion), 
as determined by GISTIC 2.0 [22], in samples with high (top quartile) and low (all others) 
pathway activity were calculated by a Fisher’s exact test.. To identify genes that were 
significant across both methods, a threshold of q<0.05 was set for validation and q<0.01 for 
discovery.
Genome-wide RNAi proliferation data
To identify genes required for cell viability in a pathway-dependent manner, data from a 
genome-wide RNAi screen in a panel of breast cancer cell lines were analyzed [6, 23]. The 
Gene Activity Ranking Profile (GARP) normalized data were obtained from the DPSC 
(Donnelly-Princess Margaret Screening Centre) data portal (http://dpsc.ccbr.utoronto.ca/
cancer/index.html) and filtered to include those 27 cell lines for which gene expression data 
(GSE12777) was also available (acquired February 2013). A negative Spearman correlation 
was used to compare pathway score and GARP score for each sample to identify genes 
essential for pathway-dependent cell proliferation. A threshold of p<0.05 was considered 
significant.
Cell culture and siRNA knockdown
HCC38, HCC1143, and MDAMB468 cells were purchased from the American Tissue 
Culture Collection (Manassas, VA, USA). Cells were cultured in either RPMI-1640 medium 
with 10% fetal bovine serum and 1% penicillin/streptomycin (HCC38 and HCC1143) or 
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DMEM/F12 medium with 10% fetal bovine serum and 1% penicillin/streptomycin 
(MDAMB468). Cells were sub-cultured at 60–70% confluence for siRNA transfections. 
Lipofectamine RNAiMAX (ThermoFisher) was used to transfect cells with 40nm of 
SMART pool siRNA targeting SOX4 (M011779010005) or scrambled control 
(D0012061305) according to manufacturer’s instructions (Dharmacon) for 48 hours prior to 
RNA or protein isolation.
Western blot
HCC38 cells were harvested using Triton lysis buffer containing 25mM HEPES, 100mM 
NaCl, 1mM EDTA, 10% glycerol and 1% TritonX-100 with 1X protease and phosphatase 
inhibitor added fresh prior to use. 50 μg of protein was loaded on 4–20% Mini-protean TGX 
gradient gel (Biorad) at 100V for 2 hours at room temperature and transferred onto 
nitrocellulose membrane at 100V for 1 hour at 4°C. The membranes were blocked using 5% 
milk solution, incubated with primary antibody against p-Akt, total Akt and beta-actin (Cell 
Signaling Technology) overnight at 4°C followed by incubation with HRP-conjugated 
secondary antibodies (Cell Signaling Technology) for 1 hour at room temperature. The 
signal was developed using SuperSignal West Pico Chemiluminescent Substrate 
(ThermoFisher Scientific), digitally imagined using the ChemiDoc Touch Imagining System 
(BioRad) and signaling intensity quantified by Image J software (https://imagej.nih.gov/ij/).
Immunofluorescence
Cells were grown on coverslips, fixed with 4% paraformaldehyde in PBS and permeabilized 
with 0.25% Triton X-100 in PBS for 8 minutes at room temperature. Cells were blocked in 
1% BSA in PBS with 0.05% Tween20 for 45 minutes at room temperature, incubated with 
anti-SOX4 (Santa Cruz, sc-17326) and anti-pAKT (Cell Signaling, 9271S) antibodies (1 
hour, room temperature) and then incubated with fluorochrome-labeled secondary antibodies 
for 1 hour (room temperature). The coverslips were counterstained with DAPI and imaged 
with a Nikon Eclipse TE-2000U fluorescent microscope.
Quantitative real time PCR
Total RNA was isolated using RNeasy plus Mini Kit (Qiagen) and cDNA was synthesized 
using the QuantiTect Reverse Transcription kit (Qiagen). Quantitative PCR (qPCR) was 
performed and analyzed using Applied Biosystems 7500 real time thermal cycler system. 
Human SOX4 primer sequences: Forward: 5′-CTCTCCAGCCTGGGAACTATAA-3′, 
Reverse: 5′-CGGAGGTGGGTAAAGAGAGAA-3′ and human GAPDH are Forward: 5′-
TCTGACTTCAACAGCGACAC -3′, Reverse: 5′-CCAGCCACATACCAGGAAAT -3′.
RESULTS
PI3K gene expression signature corresponds with PI3K/Akt signaling in vivo
We used four previously published PI3K gene expression signatures, PI3K [6, 16], PIK3CA 
[17], PTEN Wild-type (PTENWT) and PTEN Deleted (PTENDEL) [18], to calculate PI3K 
pathway activity in 1,031 human breast tumor samples (Supplementary Table 1) from the 
TCGA project for which the PAM50 intrinsic subtypes [19, 24] were determined (Figure 
1a). Although each signature was independently developed [6, 17, 18], consistent patterns of 
Mehta et al. Page 4













pathway activity were observed across molecular subtypes with basal-like tumors being 
characterized by uniformly high levels of PI3K activity; increased signaling was also 
observed in HER2-Enriched (HER2E) and Luminal B (LumB) tumors and significant 
differences were noted between each subtype (Supplementary Figure 1). Despite the fact 
that each signature was developed using different strategies, identifying differentially 
expressed genes when comparing either GFP expressing cell lines to mutant [17] or wild-
type [6, 16] PIK3CA expressing cells or by comparing PTEN wild-type and deleted tumors 
[18], signature scores were moderately concordant (r=0.4 – 0.67) across the data (Figure 1b 
and Supplementary Figure 2).
Focusing on the PI3K signature [6, 16], we confirmed the ability of the mRNA signature to 
accurately assess functional activation of the pathway by examining relationships between 
the gene expression signature score and proteins and phospho-protein expression. Analysis 
of Reverse Phase Protein Array (RPPA) data from breast tumors (n=733), using, both a 
Spearman correlation (comparing pathway score to protein expression level) and t-test (top 
quartile against all other samples), confirmed that tumors with a high PI3K score have 
significantly lower levels of PTEN and INPP4B protein expression, consistent with role of 
these proteins as negative regulators of PI3K/Akt signaling. Despite lower levels of total Akt 
and no differences in the expression of the p110-alpha or p85 kinase subunits, tumors with 
high pathway score expressed significantly higher levels of phosphorylated (p) Akt at S473 
and T308 (Figure 1c, Supplementary Table 2). In addition, a number of known drivers of 
PI3K activity, including EGFR (pY1068 and pY1173), FOXM1, NOTCH1, cKIT, SYK, 
SRC (pY416), and c-MET (pY1235), had significantly higher levels of protein expression in 
tumors with a high PI3K score. Importantly, we also observed increased levels (p<0.05) of 
activated Akt substrates including PRAS40 (pT246), p27 (pT198) and YB1 (pS102) as well 
as further down-stream targets S6 (pS235-S236 and pS240-S244) and 4EBP1 (pT70) 
(Figure 1c, Supplementary Table 2) [8, 10].
Identification of copy number alterations associated with PI3K signaling
We next sought to identify PI3K-specific copy number (CN) alterations (CNA), including 
known and potential novel drivers of pathway activity (Figure 2a). Using our previously 
published strategy [6], breast tumor samples (n=1,031) from the TCGA project were 
dichotomized into those with high (top quartile) or low (all others) pathway score and the 
frequency of copy number gains (including high level amplification and gains) or losses 
(including homozygous deletion and loss of heterozygosity) were calculated for each group 
(Figure 2b) using a Fisher’s exact test (Figure 2c). Secondly, a Spearman Rank Correlation 
was used to assess the overall relationship between PI3K pathway score and gene-level 
segment value (Figure 2c). To reduce potential false-positives associated with either strategy 
alone, we focused on those alterations that were significant (q<0.05), in both analyses; genes 
with an increased incidence of CN gains in samples with high PI3K pathway activity (top 
quartile) and a positive correlation with pathway activity were considered putative drivers of 
PI3K signaling whereas those genes with an increased frequency of CN losses in tumors 
with a high PI3K score and a negative correlation were considered potential repressors of 
PI3K activity. These analyses allow for the identification of chromosomal alterations that are 
uniquely evident in the context of PI3K signaling while eliminating those regions that, while 
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potentially altered at a high frequency, are not associated with altered signaling. For 
instance, 50.4% of patients with high PI3K activity but only 25.0% of tumors with low 
pathway activity have an amplification of chromosome 3q26, which contains PIK3CA 
(qFisher=1.5 ×10−12; qSpearman=4.0×10−10). Beyond PIK3CA amplification, we also 
identified CNA (q<0.05) of known drivers of PI3K signaling including amplification of 
KRAS, PTK2, and FOXM1 as well as losses of pathway inhibitors PTEN, INPP4B, and 
PIK3R1 (Figure 2b, Supplementary Table 3). Collectively these data suggest that this 
strategy is able to identify CNA of known PI3K signaling components and may identify 
CNA of novel regulators of this pathway.
Identification of potential essential, novel regulators of PI3K pathway activity
Our previous results identified DNA copy number aberrations that correlate with PI3K 
activity (Figure 2). By analyzing functional data from a genome-wide RNA-mediated 
interference (RNAi) screen, we are able to identify specific genes within each amplicon that 
are essential for cell viability in a pathway-dependent manner. For these analyses, we 
employed data from a genome-wide RNAi proliferation screen (~16k genes) performed in a 
panel of 27 breast cancer cell lines [23] for which matching mRNA expression data 
(GSE12777) was available (Figure 2). For each cell line, the PI3K pathway score was 
calculated and a negative Spearman rank correlation was used to identify those genes 
required for cell proliferation in a PI3K dependent manner. Our analyses identified known 
PI3K/Akt signaling components including PYK2 (Figure 3a, p=0.003) [25] as well as both 
EIF4E (Figure 3b, p=0.004) and RPS6 (Figure 3c, p=0.05), which are prominent down-
stream targets of Akt activity thereby validating this strategy.
Next we used these functional data to prioritize candidate genes within each amplicon 
associated with PI3K activity. To do so we compared the subset of genes that were amplified 
in a greater percentage (q<0.01) of samples with high PI3K pathway activity, had a positive 
correlation between PI3K signature score and CN segment score (q<0.01), and which were 
required for cell viability (p<0.05) in a PI3K-dependent manner (Figure 3d). This subset of 
genes was further restricted to those that also showed a positive correlation between DNA 
CN status and mRNA expression (Figure 3e) based on the reasoning that a potential 
regulator of pathway activity must not only be amplified but also have increased mRNA 
expression (Supplementary Table 4). Of the identified candidate genes, several, including 
NEDD9, which has been reported [26] to serve as a scaffolding protein for Akt and required 
for breast cancer genesis, have been reported to play a role in PI3K/Akt signaling. These 
data provide evidence that this strategy has the potential to identify both known and 
potentially novel mediators of PI3K/Akt signaling.
SOX4 is a putative driver of PI3K/AKT signaling
Among the candidate genes identified on chromosome 6p22 was SOX4 (sex-determining 
region Y-related high-mobility-group box transcription factor 4), which is a previously 
described oncogenic transcription factor that has been reported to correlate with a poor 
clinical outcome in human breast cancer and other cancers [27, 28]. We determined that 
SOX4 CN positively correlated with PI3K score (Figure 4a) and mRNA expression (Figure 
4b). In total 41.5% of tumors with high pathway activity (top quartile) were characterized by 
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SOX4 CN gain compared to 22.6% of all other samples (q=2.5×10−08) (Figure 4c). This 
appears to be largely a subtype-specific event as 68.1% of tumors with high PI3K activity 
and amplified SOX4 were basal-like (Figure 4d); in total, 57.2% of all basal-like tumors 
were characterized by SOX4 amplification (Supplementary Figure 3). Furthermore, SOX4 
amplified tumors had the highest levels of SOX4 mRNA (Figure 4e, p=4.0×10−23, ANOVA; 
p<0.0001), and highest levels of PI3K activity (Supplementary Figure 4, p=3.7×10−08, 
ANOVA; p<0.0001). Analyses of the METABRIC [4] dataset (n=1,992) demonstrated a 
comparable significant correlation between PI3K pathway score and SOX4 expression 
(r=0.42, p=2.6×10−87), and SOX4 CN status (r=0.23, p=1.1×10−24), respectively, as well as 
between SOX4 expression and CN (r=0.27, p=1.5×10−34), thereby validating our findings in 
an independent cohort (Supplementary Figure 5). Importantly, our analyses of data from a 
genome-wide RNAi screen demonstrated that breast cancer cell lines with high PI3K 
activity have a greater dependency (p=0.048) on SOX4 than cell lines with low PI3K activity 
(Figure 4f).
Finally, examining the coincidence of SOX4 amplification with copy number alterations of 
known drivers of PI3K signaling, demonstrated that the frequency of SOX4 amplification in 
tumors with high (or low) PI3K activity was comparable (q<0.05) to that of PIK3CA (50.4% 
vs. 25.0%), PTEN (46.9% vs. 25.5%) or INPP4B (37.6% vs. 24.8%) CNA (Figure 4a). 
These alterations, however, were neither mutually inclusive nor mutually exclusive as SOX4 
was solely altered (19.1%) at a comparable frequency to PTEN (23.6%) or INPP4B (18.7%) 
loss, or PIK3CA gain (21.7%) alone (Supplementary Figure 6).
Increased PI3K/AKT signaling in breast tumor samples with amplified SOX4
We next determine whether patients with amplified SOX4 are characterized by increased 
expression of Akt substrate proteins relative to those tumors that have a normal copy 
number. Analysis of RPPA-based protein expression in breast tumors with amplified 
(n=198) and normal (n=431) SOX4 (Figure 5a) demonstrated up-regulation of pAkt 
substrates in SOX4 amplified tumors including pPRAS40 pT246 (p=0.01); p27 pT157 
(p=0.004) and pT198 (p=1.8×10−05), and ARAF pS299 (p=0.02). Furthermore, we 
determined that down-stream targets p4EBP1 [both pS65 (p=0.001) and pT37 
(p=4.8×10−05)] and pS6 at pS235-pS236 (p=0.001) and pS240-S244 (p=0.0007) were also 
up-regulated in SOX4 amplified tumors. Consistent with these findings, we determined that 
tumors characterized by loss of PTEN (n=227), relative to samples with normal PTEN 
(n=436), showed consistent up-regulation of this subset of Akt substrates and down-stream 
target proteins (Figure 5b). As such, these data support the association of SOX4 with altered 
PI3K/Akt signaling.
SOX4 mediates PI3K/Akt signaling in basal-like breast cancer
In order to confirm that SOX4 contributes to altered PI3K signaling, we utilized gene 
expression data from a panel of 51 breast cancer cell lines (GSE12777) to identify those 
with the highest PI3K score (Supplementary Figure 7). Of these, basal-like cell lines, 
HCC38 and HCC1143 both have high PI3K signature score and high SOX4 expression 
whereas MDAMB468 cells have high PI3K activity but low (below the dataset median) 
SOX4 expression. In addition to high PI3K activity, each of these cell lines are characterized 
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by either loss of PTEN (HCC38) or EGFR activation (HCC1143) or both PTEN loss and 
EGFR activation (MDAMB468).
Using these cell lines, we examined the effects of siRNA-mediated silencing of SOX4 on 
Akt phosphorylation. Quantitative Real-time PCR (qRT-PCR) confirmed that cells 
transfected with pooled siRNA comprised of a panel of four individual siRNA targeting 
SOX4 resulted in a significant decrease in SOX4 expression in HCC38 (90%, p=0.002, 
paired t-test), HCC1143 (79%, p=0.003, paired t-test) and MDAMB468 (70%, p=0.0001, 
paired t-test) cells, respectively, relative to scrambled control (siC) transfected cells (Figure 
6a). Loss of SOX4 resulted in a significant reduction in Akt phosphorylation in both HCC38 
and HCC1143 while no change in pAkt levels were observed in MDAMB468 cells; total Akt 
or β-actin levels were unaffected (Figure 6b). Quantitative analyses of pAkt levels relative to 
total Akt (Figure 6c) demonstrated that loss of SOX4 resulted in a 54% to 56% reduction in 
pAkt levels, relative to siC treated cells, in HCC38 (p=0.0008) and HCC1143 (p=0.005), 
respectively while no quantifiable change was observed in MDAMB468 cells (p=0.53).
Analysis of siC and siSOX4 treated cells by immunofluorescent microscopy (IF) further 
demonstrates that SOX4 is largely undetectable in siSOX4-treated HCC38 cells and this loss 
of SOX4 protein expression corresponds with nearly an equal reduction in the levels of pAkt 
(Figure 6d). Interestingly, the subset of siSOX4 treated HCC38 cells which retain detectable 
levels of SOX4 also express pAkt suggesting that our western blot analyses may 
underestimate the total effect of SOX4 on pAkt levels and when compared on a cell to cell 
basis, SOX4 has a more dramatic effect on the phosphorylation of Akt. As shown in 
Supplementary Figure 8, similar effects on pAkt levels were observed after SOX4 silencing 
in HCC1143 cells.
DISCUSSION
PI3K/Akt/mTOR signaling regulates many predominant features of cancer including cellular 
proliferation, survival, metabolism, motility and genomic instability [8, 9]. This pathway not 
only contributes to tumor development, but also plays an essential role in regulating 
therapeutic resistance in breast cancer [29–31]. Not surprisingly, there has been a significant 
effort to elucidate mechanisms regulating PI3K signaling in order to identify potential 
therapeutic targets and/or biomarkers to current therapies.
Improper activation of this pathway occurs through various molecular mechanisms 
including, among others, PIK3CA activating mutations; PTEN silencing mutations; and/or 
copy number changes in PIK3CA, PTEN, INPP4B or AKT2, depending on the type and/or 
subtype of cancer [8–10]. In breast cancer, approximately 45% of patients are characterized 
by PIK3CA activating mutations [1, 3]; however these alterations are largely limited to 
LumA tumors and the link between these mutations and pathway activation is unclear as 
there is no correlation with known markers of pathway activity including pAkt, pS6 or 
p4EBP1 [3, 32–34]. In contrast basal-like or TNBC tumors are characterized by increased 
PI3K activity and have increased expression of these markers despite the fact that these 
tumors rarely have PIK3CA activating mutations [3, 12]. While clinical studies have 
demonstrated that the combination of everolimus plus exemestane resulted in an improved 
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prognosis for patients with advanced stage, ER+ luminal breast cancer [35–37], similar 
success has not been achieved in TNBC.
In the current study, we sought to identify genomic alterations that contribute to PI3K/Akt 
signaling and which may represent putative therapeutic opportunities. To address this 
challenge, we analyzed genomic data from more than 1,000 breast tumor samples from the 
TCGA [1, 3] within the framework of an experimentally derived PI3K gene expression 
signature [6]. These in silico analyses identified SOX4 as putative novel regulator of PI3K 
signaling and this association was validated in an independent cohort of nearly 2,000 breast 
tumor samples [4]. Since, altered expression of this gene predominantly occurs in basal-like 
tumors, these data, consistent with previous studies demonstrating increased SOX4 
expression in TNBC, suggest that this may be a subtype-specific event [38].
SOX4 is member of the group C family of SOX transcription factors which play an essential 
role in development but are reported to be over-expressed in many human cancers, including 
breast cancer where expression correlates with tumor grade, stage and prognosis [27, 28, 
39]. Previous studies have reported that SOX4 contributes to tumor development and 
progression through a number of mechanisms. SOX4 has been shown to be essential in 
maintenance of stemness in cancer initiating cells, in driving cell proliferation, by promoting 
cell migration and metastasis and, more recently, through induction of epithelial-to-
mesenchymal transition (EMT) in breast cancer [38, 40–43]. While these previous studies 
have demonstrated a significant role for SOX4 in tumor development, the current study is 
first to identify SOX4 as a mediator of PI3K/Akt signaling in breast cancer. These results are 
consistent with recent work that demonstrates a role for SOX4 in regulating PI3K activity in 
Ph+ ALL (Acute Lymphoblastic Leukemia) [44].
Experimental studies demonstrate that SOX4 regulates pAkt expression in breast cancer cell 
lines with high SOX4 expression irrespective of whether these cells are characterized by loss 
of PTEN or activation of EGFR. While the exact mechanism by which SOX4 modulates 
PI3K/Akt signaling remains to be determined, a number of recent studies offer insight into 
several potential mechanisms. The role of SOX4 as a transcription factor suggests that its 
effect on the PI3K pathway is mediated through regulation at the transcript level. However, 
given that our data demonstrate a clear loss of phosphorylated Akt in the absence of SOX4 
expression, but no discernible difference in total Akt, the effect of SOX4 on signaling 
appears to be upstream of Akt. It was recently reported that SOX4 cooperates with PTEN 
loss to mediate prostate cancer tumorigenesis [45]; however given that we see a comparable 
effect on SOX4-mediated Akt phosphorylation in both PTEN normal and PTEN deleted 
cells, it is unclear whether this is also true in breast cancer. The potential does exist that 
SOX4 could mediate PTEN activity. In fact, studies in hepatocellular carcinoma recently 
reported that SOX4 can modulate HUNK kinase (Hormonally-upregulated Neu-associated 
kinase) expression, which itself, has been shown to regulate Akt signaling in breast cancer 
by repressing PTEN activity [46, 47]. Unfortunately, we see no difference in HUNK mRNA 
expression in SOX4 amplified and normal breast tumors.
Alternatively, a number of studies have suggested that SOX4 can mediate activation of 
potential up-stream drivers of PI3K signaling including transcriptional activation of EGFR 
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[48]. Despite these findings in prostate cancer, we see a SOX4-mediated effect on pAkt 
levels in both EGFR activated and normal breast cancer cell lines. Moreover, we do not see a 
difference in pEGFR protein expression in SOX4 amplified or normal breast tumors. 
Although these data do not eliminate the possibility that SOX4 mediates its effect on pAkt 
through EGFR, or another receptor tyrosine kinase, it suggests that alternative breast cancer 
specific mechanisms may exist. Perhaps not surprising, recent analyses have also shown 
little concordance between genes regulated by SOX4 across tissues type including prostate, 
lung, hepatocellular carcinoma and adenoid cystic carcinoma [27, 28]. Thus, these results 
suggest the effects of SOX4 on PI3K signaling, may be affected by tissue specific features. 
As such, additional studies must be undertaken to delineate these breast cancer specific 
mechanisms.
Collectively, our cross-platform analyses of orthogonal genomic and proteomic data, along 
with in vitro studies, have identified and validated SOX4 amplification as a mediator of 
PI3K/Akt signaling in breast cancer. While the precise mechanisms by which SOX4 
modulates PI3K activity in breast cancer remain unknown, our data, in combination with 
previous studies, suggest that an emphasis should be placed on elucidating these 
mechanisms but also that SOX4, or its downstream targets, may be a putative therapeutic 
target and/or biomarker in breast cancer patients whose tumors are characterized by high 
PI3K activity.
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Figure 1. PI3K gene expression signature correlates with protein expression of PI3K/Akt 
pathway and is up-regulated in basal-like and HER2E tumors
(A) Patterns of PI3K signaling in breast cancer (n=1,031) correspond with molecular 
subtype with basal-like (red) and HER2E (pink) having the highest levels, Luminal B (light 
blue) and Normal-like (NL, green) having intermediate levels, and LumA (dark blue) having 
the lowest levels. Tumors show consistent patterns of pathway activity across independent 
gene expression signatures. (B) PI3K pathway gene expression signatures are strongly 
correlated as calculated by a Pearson correlation (C) PI3K signature (n=733) corresponds 
with protein and phosphorylated protein expression of PI3K/Akt signaling pathway 
components. A t- test (‡) was used to assess protein expression levels between the top 
quartile and all other samples and a Spearman rank correlation (†) was used to assess the 
overall relationship between pathway score and RPPA expression level.
Mehta et al. Page 13













Figure 2. PI3K score identifies PI3K/Akt specific copy number changes
(A) Overview of method for identifying PI3K-specific CNA. (B) The frequency of copy 
number gains (including amplification and gains) and losses (both deletion and LOH) were 
calculated for each gene in the top quartile (black line) and all other samples (gray line); 
frequencies are plotted according to chromosomal position. (C) A Fisher’s exact test was 
used to assess differences in the frequency of copy number gains (black line) or losses (dark 
blue line) between the top quartile and all other samples. A positive (red line) or negative 
(light blue line) Spearman rank correlation was used to assess the overall relationship 
between pathway score and gene level copy number expression.
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Figure 3. Identification of amplified and essential genes associated with PI3K signature
Identification of genes essential for cell viability in RNAi screen of breast cancer cell lines 
(n=27) in the context of PI3K signature as calculated by negative Spearman correlation 
(p<0.05) including A) PKY2 (p=0.003), (B) EIF4E (p=0.004), and (C) RPS6 (p=0.05). The 
height of each bar indicates shRNA abundance (and cell viability) for each cell line grown in 
the presence of gene-specific shRNA relative to control shRNA. (D) Schematic outlining the 
strategy used to identify amplified, essential pathway-specific genes. (E) Venn diagram 
identifying subset of amplified (q<0.01, n= 5,350) and essential (n=590) candidate genes 
that have a positive (p<0.05) correlation between mRNA expression and copy number level 
(n=100).
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Figure 4. Identification of SOX4 amplification as a putative driver of PI3K/Akt signaling
(A) Copy number alterations of modulators of PI3K/Akt signaling PIK3CA, PTEN, INPP4B 
as well as SOX4 copy number status correlates (q<0.01) with PI3K score (#). (B) SOX4 
mRNA expression correlates with PI3K score and SOX4 gene level copy number segment 
score (*). (C) SOX4 is amplified at a significantly greater frequency of samples with high 
(top quartile) PI3K pathway activity (41.5%) compared to all other samples (22.6%) 
(q=2.5×10−08). (D) Samples with an amplification of SOX4 are predominantly (68.1%) 
basal-like tumors. (E) SOX4 mRNA expression correlates with SOX4 copy number status 
(p=3.4×10−23). (F) SOX4 is essential for cell viability is breast cancer cell lines with high 
PI3K pathway activity. Higher expression of the PI3K Score is associated with lower SOX4 
shRNA abundance. (Spearman correlation, p=0.048)
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Figure 5. SOX4 amplified tumors are characterized by increased PI3K/Akt protein and 
phosphoprotein expression
(A) Breast cancer samples with a SOX4 copy number gain (n=198) had increased levels of 
expression of active or phosphorylated Akt substrates (both direct and down-stream targets) 
compared to samples with normal levels of SOX4 (n=431). (B) Comparable patterns (as 
determined by unpaired t-test) were observed in samples with a loss of PTEN (n=227) 
compared to tumors with normal PTEN copy number status (n=436).
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Figure 6. Sox4 mediates pAkt expression in vitro
(A) SOX4 mRNA levels were determined by quantitative RT-PCR in HCC38 (p=0.002), 
HCC1143 (p=0.0158) and MDA-MB-468 (p=0.0041) cells transfected with either 40nm of 
control siRNA (siC) or with siRNA against SOX4 (siSOX4) for 48 hours. Fold changes are 
relative to those of cells transfected with control siRNA and significance was calculated 
using paired t-test. (B) Immunoblot analyses of p-Akt (S473), total Akt and β-actin 
expression in cell lines with high (HCC38, HCC1143) and low (MDA-MB-468) SOX4 
expression following transfection with either siC or siSOX4. Intensity of the signal was 
measured for each protein by Image J and p-Akt (S473) expression was analyzed relative to 
Total AKT (C) for HCC38 (p=0.002), HCC1143 (p=0.005) and MDA-MB-468 (p=0.5310) 
cell lines. (D) Immunofluorescence microscopy was used to analyze the effects of siC or 
siSOX4 in HCC38 cells on SOX4 (Cy3) or pAkt (Cy5) protein expression and cell nuclei 
were visualized by DAPI; scale bar, 100 μm. Images are shown at 20x magnification (left) 
and digitally enlarged to show detail (right).
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